Topical cyclosporin-containing preparation and use of the same
Patent Information
- Application Number
- JP2024146154
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2016-03-21
- Filing Date
- 2024-08-28
- Publication Date
- 2024-11-26
- Estimated Expiration
- 2037-02-28
AI Technical Summary
Existing ophthalmic formulations containing cyclosporine suffer from side effects such as decreased vision, blurred vision, increased lacrimation, eye discharge, and taste abnormalities, and are not stable during large-scale production and handling.
Topical ophthalmic formulations containing 0.087-0.093% cyclosporine, combined with polyoxyl lipids or fatty acids and polyalkoxylated alcohols, form nanomicelles with particle sizes ranging from 1 to 100 nm, providing stability and reducing side effects.
The formulations maintain stability at elevated temperatures, resist settling, and significantly reduce side effects, offering improved safety and handling during industrial production.
Smart Images

Figure 00000000_0000_ABST
Abstract
Description
[Technical field]
[0001] The present disclosure relates to a cyclosporine-containing formulation for topical administration thereof, e.g., 0.087 to 0. Ophthalmic preparations containing 0.93% cyclosporine, as well as methods for producing such preparations and and methods of use. [Background technology]
[0002] The information provided herein and the references cited are solely to aid the reader. No admission is made that any of the references or information is prior art to the present invention. It is not something that happens.
[0003] U.S. Patent Application Publication No. 2010 / 0310462 and U.S. Patent Application Publication No. 2009 / 0310463 No. 0092665 discloses a nanomicelle containing vitamin E TPGS for ophthalmic use. A drug delivery system for the treatment of pulmonary arterial disease has been disclosed.
[0004] Travoprost is indicated for the reduction of elevated intraocular pressure in patients with glaucoma or ocular hypertension. It is an ophthalmic solution formulation. It contains 0.5% HCO-40, 0.004% active ingredient. and propylene glycol as the organic solvent. Contains. (nlm.nih.gov / dailymed / lookup.cfm?s etid=338e7ff4-0d91-4208-a45d-bfa2be52334 However, this composition is Not in the form of Nomicell. (ema.europa.eu / docs / en_GB / do cument_library / EPAR_-_Product_Informatio n / human / 000665 / WC500038389.pdf on the wo rld-wide web).
[0005] U.S. Patent No. 8,980,839 describes an aqueous ophthalmic solution containing cyclosporine, poliovirus, and cyclosporine. Solutions containing polyoxylated lipids or fatty acids and polyalkoxylated alcohols are disclosed. The patent describes HCO-40 as a polyoxyl lipid, and polyalkoxy Octoxynol-40 is proposed as the substituted alcohol.
[0006] Use of RESTATIS® (cyclosporine 0.05% ophthalmic emulsion) The most common side effect after use was burning eyes in patients, reported in 17% of cases. Other side effects include conjunctival congestion, tearing, eye pain, eye discharge, foreign body sensation, scratching, pricking and tearing. These include visual impairment (in 1-5% of patients). [Prior art documents] [Patent documents]
[0007] [Patent Document 1] US Patent Application Publication No. 2010 / 0310462 [Patent Document 2] US Patent Application Publication No. 2009 / 0092665 [Patent Document 3] U.S. Patent No. 8,980,839 Summary of the Invention [Means for solving the problem]
[0008] The present disclosure relates to a topical ophthalmic formulation comprising 0.087 to 0.093% by weight of cyclosporine. In certain aspects and embodiments, 0.08 as described herein Formulations containing 7 to 0.093% by weight of cyclosporine have been shown to be suitable for use in other ophthalmic formulations, e.g. Side effects as reported with DRA® (lifitegrast ophthalmic solution), including does not cause decreased vision, blurred vision, increased tearing, eye discharge, or abnormal taste, and therefore This provides a better safety profile.
[0009] The formulations disclosed herein contain 0.087 to 0.093% by weight of cyclosporine. The surprising fact that the compounds can be highly effective and, for example, can be unexpectedly stable in large-scale production. The present invention is based, at least in part, on unexpected findings that could not be predicted prior to the present disclosure. Among the features and advantages of the formulation of the present disclosure are its improved handling after preparation on an industrial scale. Thus, various aspects and embodiments of the formulations of the present disclosure include, but are not limited to, a carrier It remains completely fluid at room temperature and resists any tendency to settle when handled.
[0010] In certain embodiments, the formulations of the present disclosure may be used at elevated temperatures, e.g., temperatures above about 40° C. It is surprisingly stable.
[0011] In certain aspects and embodiments, the formulations of the present disclosure comprise a polyoxyl lipid or The nanomicelles further comprise fatty acids, and / or polyalkoxylated alcohols. That's fine too.
[0012] Nanomicelles contemplated in the present disclosure typically have a particle size in the range of about 1 to 100 nm. In some embodiments, the particle size is in the range of about 5 to 50 nm; In embodiments, the particle size falls in the range of about 10 to 40 nm; in some embodiments The particle size is about 15 nm.
[0013] In one embodiment, the topical ophthalmic formulation of the present disclosure comprises 0.087-0.093% by weight of cyclohexylglycerol. The formulation comprises a sporin, and one or more additional formulation ingredients.
[0014] In one embodiment of the above aspect, the formulations contemplated herein are resistant to oxidative stress at temperatures above 40° C. It is stable at this temperature.
[0015] In another embodiment of the above aspect, the formulation of the present disclosure is a clear aqueous solution.
[0016] In another embodiment of the above aspect, the formulation of the present disclosure is substantially free of organic solvents.
[0017] In another embodiment of the above aspect, the formulation of the present disclosure does not contain a preservative.
[0018] In another embodiment of the above aspect, the formulation of the present disclosure further comprises one or more additional formulation components. Includes.
[0019] In another embodiment of the above aspect, the formulation of the present disclosure is a mixed nanomicelle formulation.
[0020] In another embodiment of the above aspect, the formulation of the present disclosure is encapsulated in the core of a mixed nanomicelle. Contains cyclosporine.
[0021] In another embodiment of the above aspect, the nanomicelle has a particle size of about 5 to 100 nm. do.
[0022] In another embodiment of the above aspect, the formulation of the present disclosure includes one or more additional ingredients. nothing.
[0023] In another embodiment of the above aspect, the additional component is a polyoxyl lipid or a fatty acid, such as and polyalkoxylated alcohols.
[0024] In another embodiment of the above aspect, the polyoxyl lipid is polyoxyl castor oil. .
[0025] In another embodiment of the above aspect, the polyoxyl lipid is HCO-40, HCO-60 , HCO-80, and HCO-100.
[0026] In another embodiment of the above aspect, the polyoxyl lipid or fatty acid comprises about 0.1 It is present in an amount of .about.5% by weight.
[0027] In another embodiment of the above aspect, the polyalkoxylated alcohol is an octoxylated alcohol. It is number 40.
[0028] In another embodiment of the above aspect, the polyalkoxylated alcohol comprises about 0.0% of the formulation. It is present in an amount of 0.2-4% by weight.
[0029] In another embodiment of the above aspect, the formulations of the present disclosure that include additional formulation components include additives, supplements, Further selected from the group consisting of auxiliary agents, buffering agents, tonicity agents, bioadhesive polymers, and preservatives. will be done.
[0030] In another embodiment of the above aspect, the buffer is selected from the group consisting of phosphate, borate, acetate, citrate, and the like. The polyol is selected from the group consisting of salts, carbonates, and borate-polyol complexes.
[0031] In another embodiment of the above aspect, the tonicity agent is mannitol, sodium chloride, nitric acid Sodium, sodium sulfate, dextrose, xylitol, or a combination The compound is selected from the group consisting of:
[0032] In another embodiment of the above aspect, the bioadhesive polymer is carbopol, carbophy cellulose derivatives, gums such as xanthan, karaya, guar, tragacanth, almonds, Galvanized sugar, and other polymers such as povidone, polyethylene glycol, poloxamer, mer, hyaluronic acid, or a combination thereof.
[0033] In another embodiment of the above aspect, the bioadhesive polymer is povidone.
[0034] In certain aspects and embodiments, the formulations of the present disclosure further comprise an active agent.
[0035] In certain embodiments of the above aspects, the additional active ingredient is a resolvin, a resolvin-like compound, Compounds, steroids, antibiotics, antivirals, hormones, cytokines, toxins, vitamins or a combination thereof.
[0036] In certain aspects and embodiments, the formulations of the present disclosure have a molecular weight of 0.087 to 0.093. % cyclosporine, the formulations showed clinically significant tear production compared to vehicle. improvement, with an increase in Schimer test score of 10 mm or more from baseline do.
[0037] In some embodiments of the above aspects, the formulations of the present disclosure have a lower cyclosporine A activity than other formulations. It shows an earlier onset of action compared to
[0038] In certain aspects and embodiments, the formulations of the present disclosure comprise: 0.087 to 0.093% by weight of cyclosporine, about 0.1 to 6% by weight of hydrogenated 40 polyoxyl castor oil, and Approximately 0.002 to 4% by weight of Octoxynol-40 Includes.
[0039] In certain aspects and embodiments, the formulations of the present disclosure comprise: 0.087 to 0.093% by weight of cyclosporine, about 1.0% by weight of hydrogenated 40 polyoxyl castor oil, and Approximately 0.05% by weight of Octoxynol-40 (Igepal) In certain aspects and embodiments, the formulations of the present disclosure include Approximately 0.20 to 0.405% by weight of sodium phosphate monobasic monobasic), Approximately 0.23 to 0.465% by weight of sodium phosphate dibasic dibasic), about 0.05% by weight of sodium chloride, about 0.3% by weight of Povidone K90, Sodium hydroxide / hydrochloric acid, and water for injection Further includes:
[0040] As used herein in connection with numerical values, the term "approximately" means "y") and "about" mean ±10% of the stated value, inclusive. Taste.
[0041] In some embodiments, the formulations contemplated herein contain 0.088 to 0.093% by weight Contains cyclosporine.
[0042] In some embodiments, the formulations contemplated herein contain 0.089 to 0.093% by weight In some embodiments of such aspects, the formulation of the present disclosure comprises: 0.089 to 0.093% by weight of cyclosporine, about 1.0% by weight of hydrogenated 40 polyoxyl castor oil, and Approximately 0.05% by weight of Octoxynol-40 (Igepal) In certain aspects and embodiments, the formulations of the present disclosure include About 0.20% by weight sodium phosphate monobasic, About 0.23% by weight sodium phosphate dibasic, about 0.05% by weight of sodium chloride, about 0.3% by weight of Povidone K90, Sodium hydroxide / hydrochloric acid, and water for injection Further includes:
[0043] In some embodiments of such aspects, the formulation of the present disclosure comprises: 0.09 to 0.093% by weight of cyclosporine, about 1.0% by weight of hydrogenated 40 polyoxyl castor oil, and Approximately 0.05% by weight of Octoxynol-40 (Igepal) In certain aspects and embodiments, the formulations of the present disclosure include About 0.405% by weight sodium phosphate monobasic, About 0.465% by weight sodium phosphate dibasic, about 0.05% by weight of sodium chloride, about 0.3% by weight of Povidone K90, Sodium hydroxide / hydrochloric acid, and water for injection Further includes:
[0044] In some embodiments, the formulations contemplated herein contain 0.091 to 0.093% by weight Contains cyclosporine.
[0045] In some embodiments, the formulations contemplated herein contain 0.092 to 0.093% by weight Contains cyclosporine.
[0046] In some embodiments, the formulations contemplated herein contain 0.087 to 0.092% by weight Contains cyclosporine.
[0047] In some embodiments, the formulations contemplated herein contain 0.087 to 0.091% by weight Contains cyclosporine.
[0048] In some embodiments, the formulations contemplated herein contain 0.087 to 0.09% by weight of cysteine. In some embodiments of such aspects, the formulation of the present disclosure comprises: 0.087 to 0.09% by weight of cyclosporine, about 1.0% by weight of hydrogenated 40 polyoxyl castor oil, and Approximately 0.05% by weight of Octoxynol-40 (Igepal) In certain aspects and embodiments, the formulations of the present disclosure include About 0.20% by weight sodium phosphate monobasic, About 0.23% by weight sodium phosphate dibasic, about 0.05% by weight of sodium chloride, about 0.3% by weight of Povidone K90, Sodium hydroxide / hydrochloric acid, and water for injection Further includes:
[0049] In some embodiments of such aspects, the formulation of the present disclosure comprises: 0.087 to 0.089% by weight of cyclosporine, about 1.0% by weight of hydrogenated 40 polyoxyl castor oil, and Approximately 0.05% by weight of Octoxynol-40 (Igepal) In certain aspects and embodiments, the formulations of the present disclosure include About 0.405% by weight sodium phosphate monobasic, About 0.465% by weight sodium phosphate dibasic, about 0.05% by weight of sodium chloride, about 0.3% by weight of Povidone K90, Sodium hydroxide / hydrochloric acid, and water for injection Further includes:
[0050] In some embodiments, the formulations contemplated herein contain 0.087% by weight cyclosporin. Includes
[0051] In some embodiments, the formulations contemplated herein contain 0.088% by weight cyclosporin. Includes
[0052] In some embodiments, the formulations contemplated herein contain 0.089% by weight cyclosporin. Includes
[0053] In some embodiments, the formulations contemplated herein contain 0.09% by weight cyclosporine Includes.
[0054] In some embodiments, the formulations contemplated herein contain 0.091% by weight cyclosporin. Includes
[0055] In some embodiments, the formulations contemplated herein contain 0.092% by weight cyclosporin. Includes
[0056] In some embodiments, the formulations contemplated herein contain 0.093% by weight cyclosporin. Includes
[0057] In certain aspects and embodiments, the formulations as described herein are The pharmaceutical composition is particularly suited for delivery to the anterior segment, or to the posterior segment, or to both the anterior and posterior segments of the eye.
[0058] In certain aspects and embodiments, the formulations of the present disclosure comprise: 0.087 to 0.093% by weight of cyclosporine, about 1.0% by weight of hydrogenated 40 polyoxyl castor oil, and Approximately 0.05% by weight of Octoxynol-40 (Igepal) and optionally further comprising: About 0.20 to 0.405% by weight sodium phosphate monobasic, About 0.23 to 0.465% by weight sodium phosphate dibasic, about 0.05% by weight of sodium chloride, about 0.3% by weight of Povidone K90, NaOH / HCl, and water for injection It essentially consists of:
[0059] In some embodiments, the formulation comprises nanomicelles with relatively increased encapsulation efficiency. and in such embodiments, cyclosporine is at least about 0.087% of the formulation. %, or at least about 0.088%, or at least about 0.089%, or at least about 0.09%, or at least about 0.091%; or at least about 0 .092%, or at least about 0.093%; or 0.087% or less; or 0. 0.087~0.093%, or 0.088~0.093%, or 0.089%~0 .093%, or 0.09 to 0.093%; or about 0.087%, or about 0. 088%, or about 0.089%, or about 0.09%, or about 0.091%, or about 0.092%, or about 0.093%, in the nanomicelle of the formulation. exists.
[0060] Thus, in one embodiment, 0.087 to 0.093% by weight of cyclosporine, poly Ophthalmic formulations containing oxyl lipids or fatty acids and polyalkoxylated alcohols In some embodiments, the formulation comprises nanomicelles. In some embodiments, the polyoxyl lipid or fatty acid is polyoxyl castor oil. In the present study, the polyoxyl lipids or fatty acids are HCO-40, HCO-60, and HCO-8 0, or HCO-100. Polyoxyl lipids or fatty acids (e.g., HCO-40, HCO-60, HCO-8 0, or polyoxyl castor oil such as HCO-100) is used in the formulation at 0.5 to 5% by weight. , or 0.6 to 5% by weight, or 0.7 to 5% by weight, or 0.8 to 5% by weight, or 0.9 to 5% by weight, or 1 to 5% by weight, or 1% to 4% by weight, if or about 1-3%, or 1-2%, or about 1%, or more than 0.5%, or more than 0.6% by weight, or more than 0.7% by weight, or more than 0.8% by weight, or In some embodiments, the polyoxyethylene ether is present at greater than 0.9% by weight, or greater than 1% by weight. In some embodiments, the polyoxyl lipid is HCO-60. -80. In some embodiments, the polyoxyl lipid is HCO-100. In some embodiments, the formulation comprises a polyalkoxylated aryl ester that is octoxynol-40. In some embodiments, the formulation comprises 0.01 to 1% by weight of the formulation, if or 0.02 to 1% by weight, or 0.03 to 1% by weight, or 0.04 to 1% by weight, Or 0.05 to 1% by weight, or 0.06 to 1% by weight, or 0.07 to 1% by weight %, or 0.08 to 1 weight percent, or about 1 weight percent of polyalkoxylated arsenic. Cole (e.g., Octoxynol-40).
[0061] As used herein, the term "polyoxyl lipid or fatty acid" refers to a lipid or fatty acid. Polyoxyl refers to mono- and diesters of fatty acids and polyoxyethylene diol. A lipid or fatty acid, as is well understood in the art, is a fatty acid that is a carboxylic acid having an oxyethylene unit. Numbered ("n") by average polymer length (e.g., 40, 60, 80, 100) The term "n≧40 polyoxyl lipid" refers to a polyoxyl lipid or fatty acid having 4 It means that the oxyethylene polymer has an average polymer length equal to or greater than 0 units. Hydrogenated castor oil stearate and castor oil are polyoxyl lipids or fatty acids. However, any lipid or fatty acid may be Alternatively, fatty acids may also be polyoxylated to produce polyoxylated lipids or lipids as contemplated herein. It is understood that the polyoxyl lipid or fatty acid can be a fatty acid. Examples of polyoxyl lipids or fatty acids include , without limitation, HCO-40, HCO-60, HCO-80, HCO-100, Contains Polyoxyl 40 Tetrahydrofuran, Polyoxyl 35 Castor Oil.
[0062] In some embodiments of any of the compositions and methods described herein, polio The average polymer length of the oxyethylene units of the oxyl lipids or fatty acids is relatively larger. longer for active ingredients and shorter for relatively smaller active ingredients; e.g. In some embodiments, where the moiety is a resolvin or a resolvin-like compound, the polyoxyl The lipid is HCO-60, and the active ingredient is cyclosporine A (which is a larger molecule than resolvin). In some embodiments, the polyoxyl lipid is HCO-80 or HCO It is -100.
[0063] As used herein, the term "micelle" or "nanomicelle" refers to a surfactant molecule. Micelles are aggregates (or clusters) of surfactants that are concentrated at a critical micelle concentration (CMC). Surfactants are chemicals that are amphiphilic. which means that they contain both hydrophobic and hydrophilic groups. can exist in a variety of shapes, including spherical, cylindrical, and discoidal. Micelles that contain different molecular species are mixed micelles. In some embodiments thereof, the present disclosure The ophthalmic composition comprises an aqueous, clear, mixed micellar solution.
[0064] In another embodiment, 0.087 to 0.093% by weight of cyclosporine, and n≧40 In some embodiments, an ophthalmic formulation is provided comprising the polyoxyl lipid or fatty acid. In some embodiments, the formulation comprises a nanomicelle. The acid is polyoxyl castor oil. In some embodiments, a polyoxyl lipid or Fatty acids are selected from HCO-40, HCO-60, HCO-80, or HCO-100 In some embodiments, the lipid is one or more of a polyoxyl lipid or a fatty acid. (e.g., HCO-40, HCO-60, HCO-80, or HCO-100) Trioxyl castor oil) is used in the formulation at 0.1-2% by weight, or 0.2-2% by weight, if or 0.3 to 2% by weight, or 0.4 to 2% by weight, or 0.5 to 2% by weight, or is 0.6 to 2% by weight, or 0.7 to 2% by weight, or 0.8 to 2% by weight, or 0.9 to 2% by weight, or 1 to 2% by weight, or 0.1 to 6% by weight, or about 4% by weight %, or more than 0.4% by weight, or more than 1% by weight, or more than 1.5% by weight, or 2 %, or greater than 3% by weight, or greater than 4% by weight. In some embodiments, the polyoxyl lipid is HCO-60. The lipid is HCO-80. In some embodiments, the polyoxyl lipid is HCO- In some embodiments, the formulation further comprises a polyalkoxylated alcohol. In some embodiments, the formulation comprises a polyalkoxy group that is octoxynol-40. In some embodiments, the formulation further comprises a silyl alcohol. up to 4% by weight, or 0.005 to 3% by weight, or 0.005 to 2% by weight, or 0.005 to 1% by weight, or 0.005 to 0.5% by weight, or 0.005 to 0. 1% by weight, or 0.005 to 0.05% by weight, or 0.008 to 0.02% by weight , or 0.01 to 0.1% by weight, or 0.02 to 0.08% by weight, or 0. 0.05-0.08%, or about 0.05%, or about 0.01% by weight. Polyalkoxylated alcohols (e.g., Octoxynol-40) that are
[0065] In another embodiment, 0.087 to 0.093% by weight of cyclosporine and polyoxyethylene An ophthalmic formulation comprising a polyoxyl lipid or a fatty acid, said polyoxyl lipid or fatty acid being is present in an amount equal to or greater than 1% of said formulation. In a similar embodiment, 0.087 to 0.093% by weight of cyclosporine and poliovirus 1. An ophthalmic formulation comprising a polyoxyl lipid or a fatty acid, the polyoxyl lipid or the fatty acid comprising is present in an amount equal to or greater than 0.05% of said formulation. In some embodiments, the formulation comprises nanomicelles. In some embodiments, the polyoxyl lipid or fatty acid is polyoxyl castor oil. In the present invention, the polyoxyl lipids or fatty acids are HCO-40, HCO-60, HCO-80, or HCO-100. , polyoxyl lipids or fatty acids (e.g., HCO-60, HCO-80, or HCO -100) is used in an amount of 0.5 to 2% by weight of the formulation, or 0.7 up to 2% by weight, or 1-6% by weight, or 2-6% by weight, or 2-6% by weight, if or 3 to 6% by weight, or 4 to 6% by weight, or 2 to 5% by weight, or 3 to 5% by weight %, or 3-5% by weight, or 2-6% by weight, or about 4% by weight, or 1.5% by weight %, or greater than 2%, or greater than 3%, or greater than 4% by weight. In some embodiments, the polyoxyl lipid is HCO-40. In some embodiments, the polyoxyl lipid is HCO-60. In some embodiments, the polyoxyl lipid is HCO-80. In some embodiments, the formulation further comprises a polyalkoxylated alcohol. In some embodiments, the formulation includes a polyalcohol that is octoxynol-40. In some embodiments, the formulation further comprises an xylated alcohol. 2 to 4% by weight, or 0.005 to 3% by weight, or 0.005 to 2% by weight, or is 0.005 to 1% by weight, or 0.005 to 0.5% by weight, or 0.005 to 0 0.1% by weight, or 0.005-0.05% by weight, or 0.008-0.02% by weight %, or 0.01 to 0.1% by weight, or 0.02 to 0.08% by weight, or 0 Present at .005-0.08% by weight, or about 0.05% by weight, or about 0.01% by weight Examples of suitable polyalkoxylated alcohols include polyalkoxylated alcohols (e.g., octoxynol-40).
[0066] In another embodiment, 0.087 to 0.093% by weight of cyclosporine and polyoxyethylene An ophthalmic formulation comprising a silllipid or a fatty acid, said formulation comprising nanomicelles. In some embodiments, the polyoxyl lipid or fatty acid is a polyoxyl In some embodiments, the polyoxyl lipid or fatty acid is HCO -40, HCO-60, HCO-80, or HCO-100; or In some embodiments, a polyoxyl lipid or a fatty acid (e.g., HCO Polyoxyl castor oils such as HCO-40, HCO-60, HCO-80, or HCO-100 oil) is present in an amount of 0.5 to 2% by weight, or 0.7 to 2% by weight, or 1 to 6% by weight of the formulation; Or 2 to 6% by weight, or 2 to 6% by weight, or 3 to 6% by weight, or 4 to 6 % by weight, or 2-5% by weight, or 3-5% by weight, or 3-5% by weight, or is 2 to 6% by weight, or about 4% by weight, or more than 0.7% by weight, or more than 1% by weight, if or more than 1.5% by weight, or more than 2% by weight, or more than 3% by weight, or more than 4% by weight In some embodiments, the polyoxyl lipid is HCO-40. In some embodiments, the polyoxyl lipid is HCO-60. In some embodiments, the polyoxyl lipid is HCO-80. In some embodiments, the formulation comprises a polyalkoxylated alginate. In some embodiments, the formulation further comprises octoxynol-40. In some embodiments, the formulation further comprises a polyalkoxylated alcohol. 0.002 to 4% by weight, or 0.005 to 3% by weight, or 0.005 to 2 %, or 0.005 to 1% by weight, or 0.005 to 0.5% by weight, or 0 .005 to 0.1% by weight, or 0.005 to 0.05% by weight, or 0.008 to 0.02% by weight, or 0.01 to 0.1% by weight, or 0.02 to 0.08% by weight , or 0.005 to 0.08% by weight, or about 0.05% by weight, or about 0.01 % by weight of a polyalkoxylated alcohol (e.g., Octoxynol-40) include.
[0067] In a further embodiment, 0.087 to 0.093% by weight of cyclosporine, 1 to 5% , HCO-40, HCO-60, HCO-80 and HCO-100 and about 0.01 to 0.05% Octoxynol-40. Ophthalmic formulations are provided.
[0068] In another embodiment, 0.087 to 0.093% by weight of cyclosporine, 1 to 5% of H Selected from the group consisting of HCO-40, HCO-60, HCO-80 and HCO-100 and about 0.01 to 0.05% octoxynol-40, Ophthalmic formulations are provided.
[0069] In yet another embodiment, 0.087 to 0.093% by weight of cyclosporine, 1 to 5% selected from the group consisting of HCO-40, HCO-60, HCO-80 and HCO-100. and about 0.01 to 0.05% Octoxynol-40. An ophthalmic formulation is provided comprising:
[0070] In another embodiment, 0.087 to 0.093% by weight of cyclosporine, 1 to 5% of H Selected from the group consisting of HCO-40, HCO-60, HCO-80 and HCO-100 and about 0.01 to 0.05% octoxynol-40, Ophthalmic formulations are provided.
[0071] In a further embodiment, 0.087-0.093% by weight cyclosporine, about 4% H CO-60, and about 0.01 to 0.05% Octoxynol-40, Ophthalmic formulations are provided.
[0072] In another embodiment, 0.087 to 0.093% by weight of cyclosporine, 0.7 to 1.5 % from the group consisting of HCO-40, HCO-60, HCO-80 and HCO-100 One or more selected from the group consisting of octoxynol-4, octoxynol-5, octoxynol-6, octoxynol-7, octoxynol-8, octoxynol-9, octoxynol-10, octoxynol-11, octoxynol-4, octoxynol-12, octoxynol-13, octoxynol-14, octoxyn 0.
[0073] In another embodiment, 0.087 to 0.093% by weight of cyclosporine, 0.7 to 1.5 % from the group consisting of HCO-40, HCO-60, HCO-80 and HCO-100 and about 0.05 to 0.1% Octoxynol-40. An ophthalmic formulation is provided comprising:
[0074] In yet another embodiment, 0.087 to 0.093% by weight of cyclosporine, 0.7 to 0.87% by weight of cyclosporine, 1.5% HCO-40, HCO-60, HCO-80 and HCO-100 and about 0.05 to 0.1% of octoxynol- 40. Ophthalmic formulations are provided.
[0075] In another embodiment, 0.087 to 0.093% by weight of cyclosporine, 0.7 to 1.5 % from the group consisting of HCO-40, HCO-60, HCO-80 and HCO-100 and about 0.05 to 0.1% Octoxynol-40. An ophthalmic formulation is provided comprising:
[0076] In a further embodiment, 0.087-0.093% by weight cyclosporine, about 1% H CO-60, and about 0.05 to 0.1% Octoxynol-40, Ophthalmic formulations are provided.
[0077] In various embodiments of any of the aspects and embodiments described herein, the formulation includes nanomicelles.
[0078] In some embodiments of the aspects and embodiments described herein, the formulation is a polio vaccine. In some embodiments, the polyoxyl lipid or fatty acid may be a polyoxyl lipid or fatty acid. The acid is polyoxyl castor oil. In some embodiments, a polyoxyl lipid or Fatty acids are selected from HCO-40, HCO-60, HCO-80, or HCO-100 In some embodiments, the lipid is one or more of a polyoxyl lipid or a fatty acid. (e.g., polyoxyl castor oils such as HCO-60, HCO-80, or HCO-100) The amount of linseed oil is 0.5 to 2% by weight, 0.7 to 2% by weight, or 1 to 6% by weight of the formulation. %, or 2-6% by weight, or 2-6% by weight, or 3-6% by weight, or 4 up to 6% by weight, or 2 to 5% by weight, or 3 to 5% by weight, or 3 to 5% by weight, or 2-6% by weight, or about 4% by weight, or more than 0.7% by weight, or more than 1% by weight, Or more than 1.5% by weight, or more than 2% by weight, or more than 3% by weight, or more than 4% by weight In some embodiments, the polyoxyl lipid is HCO-40. In some embodiments, the polyoxyl lipid is HCO-60. In some embodiments, the polyoxyl lipid is HCO-80. The lipid is HCO-100.
[0079] In some embodiments of the aspects and embodiments disclosed herein, polyalkoxy In some embodiments, the formulation comprises octoxynol-40. In some embodiments, the formulation comprises a polyalkoxylated alcohol. 0.002-4% by weight, or 0.005-3% by weight, or 0.005-2% by weight, Or 0.005 to 1% by weight, or 0.005 to 0.5% by weight, or 0.00 5 to 0.1% by weight, or 0.005 to 0.05% by weight, or 0.008 to 0.0 2% by weight, or 0.01-0.1% by weight, or 0.02-0.08% by weight, if or about 0.005 to 0.08% by weight, or about 0.05% by weight, or about 0.01% by weight Examples of suitable polyalkoxylated alcohols include those present in the form of octoxynol-40.
[0080] In certain aspects and embodiments, the present disclosure provides: 0.087 to 0.093% by weight of cyclosporine, about 1.0% by weight of hydrogenated 40 polyoxyl castor oil, and Approximately 0.05% by weight of Octoxynol-40 (Igepal) and Optionally, further: 0.20 to 0.405% by weight sodium phosphate monobasic, 0.23 to 0.465% by weight sodium phosphate dibasic, about 0.05% by weight of sodium chloride, about 0.3% by weight of Povidone K90, Sodium hydroxide / hydrochloric acid, and water for injection The present invention contemplates a stable emulsion comprising:
[0081] In some aspects, the disclosure is a method of preparing a topical ophthalmic formulation of cyclosporine. So, (1) melting a required amount of polyoxyl lipid; (2) Slowly add cyclosporine to step (1) until the mixture is substantially homogenous. The process and (3) Add polyalkoxylated alcohol to step (2) to obtain a uniform, homogeneous solution. continuing the stirring until (4) Add a buffer system and an isotonicity agent to the solution obtained in step (3) and continue stirring; achieving good dissolution; (5) adding the required amount of bioadhesive polymer to the solution of the previous step; (6) if necessary, adjusting the pH of the solution and making up the final volume with water for injection; (7) sterile filtering the solution and filling it into unit dose vials;
[0023] The present invention contemplates a method comprising:
[0082] In some aspects, the present disclosure provides a method for producing a cyclosporine-containing formulation, including the formulations described above. 1. A melt-based process comprising the steps of: Melting hydrogenated 40 polyoxyl castor oil; slowly adding cyclosporine thereto, and then substantially mixing the ingredients; Octoxynol 40 (Igepal) was added to the resulting homogenous mixture, and the mixture was allowed to substantially homogenize. and then mixing the mixture until it becomes This mixture is added to water for injection, and then diluted with enough water to achieve good dissolution of each. Add excipients (e.g., sodium phosphate monobasic, sodium phosphate dibasic, and sodium chloride) separately.
[0023] The present invention contemplates a method comprising:
[0083] An exemplary melt-based manufacturing method contemplated for use herein comprises the steps of: include: Step 1: Dissolve the required amount of HCO-40 in a flask heated to about 60°C with stirring. When liquefied, add the required amount of cyclosporine and mix until dissolved. The Octoxynol-40 is then added and the entire solution is mixed until uniform. Step 2: Add the required amount of water for injection into a stainless steel container and stir until the temperature reaches 25°C. Mix. Step 3: Transfer the contents from step 1 to a stainless steel container and stir until dissolved. Step 4: Add the required amount of sodium chloride and phosphate buffer to a stainless steel vessel; The contents are mixed until dissolved. Step 5: Add the required amount of povidone to the container and stir until dissolved. Step 6: Measure and adjust (if necessary) the pH of the solution in step 5 and add water for injection to make a final solution. Convert to volume. Step 7: The solution from step 6 is sterile filtered and dispensed into form-fill-synthetic (BFS) unit dose vials. Aseptically fill into tubes with a nominal fill volume of 0.3 mL. Step 8: Package the vials in heat sealed foil pouches in 4 BFS unit strips.
[0084] In some aspects, the disclosure is a method of preparing a topical ophthalmic formulation of cyclosporine. So, (1) A required amount of cyclosporine, polyalkoxylated alcohol and polyoxyl lipid dissolving the substance in a suitable solvent; (2) placing the solution from step (1) into a suitably sized round bottom flask; (3) removing the solvent by rotary evaporation until a thin film is obtained; (4) Add the required amount of water for injection to the flask containing the membrane from step (3) and mix. The process and (5) adding a buffer system and a tonicity agent to the solution of step (4); (6) adding the required amount of bioadhesive polymer to the solution of the previous step; (7) adjusting the pH of the solution, if necessary, and making up the final volume with water for injection; (8) sterile filtering the solution and filling into unit dose vials;
[0023] The present invention contemplates a method comprising:
[0085] An exemplary solvent-based manufacturing method contemplated for use herein comprises the following steps: (1) Cyclosporine, Octoxynol-40 and Hydrogenated Polyoxyethylene 40 dissolving castor oil in a suitable solvent; (2) placing the solution from step (1) into a suitably sized round bottom flask; (3) removing the solvent by rotary evaporation until a thin film is obtained; (4) Add the required amount of water for injection to the flask containing the membrane from step (3) and mix. The process and (5) adding a phosphate buffer and sodium chloride to the solution of step (4); (6) adding the required amount of povidone to the solution of the previous step; (7) adjusting the pH of the solution, if necessary, and making up the final volume with water for injection; (8) sterile filtering the solution and filling into unit dose vials; Includes.
[0086] The present disclosure relates to the treatment of ophthalmic or ophthalmic diseases, for example, by topical administration of the formulations as described herein. relates to the treatment or prevention of a disorder.
[0087] The patient or subject to be treated by any of the compositions or methods of the present disclosure may be a human or In some embodiments, the present disclosure provides a method for detecting a human subject, comprising the steps of: In one embodiment, a method for treating an ocular disease in a human patient is provided. The present disclosure relates to a method for treating inflammatory eye disease in a human patient in need thereof. In another embodiment, the present disclosure provides, but is not limited to, a method for the treatment of a dog, horse, cat, rabbit, or the like. Giggers, gerbils, hamsters, rodents, birds, aquatic mammals, cattle, pigs, camelids In veterinary patients in need thereof, including animals and other zoological animals Methods for the treatment of diseases are provided.
[0088] In some embodiments of the compositions and methods disclosed herein, cyclosporine , one or more additional active ingredients, e.g., resolvins or resolvin-like compounds, and an active agent selected from the group consisting of steroids (e.g., corticosteroids). In some embodiments, the additional active agent includes a resolvin. In embodiments, the additional active agent includes a corticosteroid. In some embodiments, the additional active agents include resolvins and corticosteroids. In some embodiments, the additional active agent includes an antibiotic, e.g., azithromycin, Profloxacin, ofloxacin, gatifloxacin, levofloxacin, moxifloxacin one or more selected from the group consisting of fluoxacin, besifloxacin, and levofloxacin In some embodiments, the additional active agent includes an antibiotic, e.g. , Azithromycin, Ciprofloxacin, Ofloxacin, Gatifloxacin, Levof Consists of loxacin, moxifloxacin, besifloxacin, and levofloxacin The second of such agents may include one or more selected from the group Resolvins such as those described herein (including, but not limited to, compound 1001) are known to be effective in treating cancer. In embodiments, the active agent includes two or more active agents, one of which is Antiviral drugs, such as ganciclovir, trifluridine, acyclovir, famciclo cyclovir, valacyclovir, penciclovir, and cidofovir. In some embodiments, the active agents include two or more antiviral agents. The active agents include the above, one of which is an antibiotic, e.g., ganciclovir, triflurane, Luridin, acyclovir, famciclovir, valacyclovir, penciclovir, and cidofovir; and The second is a resolvin as described herein (including, without limitation, compound 100). 1 included).
[0089] The term "treating" refers to treating a subject that is susceptible to a disease, disorder, and / or condition. Cells, tissues, systems, or animals that may have a disease but have not yet been diagnosed as having it or to prevent a disease, disorder, or condition from occurring in a subject, or in a human; and / or to stabilize or halt the progression of a disease, disorder, or condition; alleviating one or more symptoms, i.e., causing the remission of a disease, disorder and / or condition; It refers to causing something to happen.
[0090] As used herein, a therapeutic agent that "prevents" a disorder or condition is a statistically significant and reducing the appearance of the disorder or condition in treated samples compared to untreated control samples. or the onset of one or more symptoms of the disorder or condition compared to an untreated control sample. delaying or reducing one or more symptoms of the disorder or condition as compared to an untreated control sample. It refers to a compound that reduces the severity of symptoms.
[0091] As used herein, the terms "ocular disease," "ophthalmic "ocular condition," "eye disease" " and "eye conditions" can be vision-threatening and can cause eye Refers to ocular diseases / conditions that can result in discomfort for the eye and signal systemic health problems. vinegar.
[0092] As used herein, the term "anterior segment disease" refers to isease) affects the ocular surface, the anterior chamber of the eye, the iris, and the ciliary body and lens. The ocular surface refers to any disorder that affects the cornea, conjunctiva, eyelids, lacrimal and meibomian glands, and It is made up of interconnected nerves.
[0093] As used herein, "posterior segment ocular disease" refers to a condition in which the posterior segment ocular "Back-of-the-eye disease" and "Back-of-the-eye disease" "Posterior eye disease" refers to any disorder that affects the back of the eye. Ocular sites, such as the choroid or sclera, the vitreous body, the vitreous cavity, the retina, the optic nerve, and the posterior ocular A disease that primarily affects the blood vessels and nerves that vascularize or innervate an area. be.
[0094] Thus, in another aspect, the present invention provides a method for the preparation of a composition comprising the steps of: A method of treating or preventing an ophthalmic disease or condition comprising topically administering any of the formulations. In some embodiments, the eye disease is an anterior segment disease. In some embodiments, the ocular disease is a posterior segment disease. In some embodiments, the ocular disease is dry eye disease. Syndrome, Sjogren's syndrome, uveitis, anterior uveitis (iritis), retinal chorioretinitis, posterior Uveitis, conjunctivitis, allergic conjunctivitis, keratitis, keratoconjunctivitis, vernal keratoconjunctivitis (VKC), Atopic keratoconjunctivitis, systemic immune-mediated diseases such as cicatricial conjunctivitis, and other diseases of the ocular surface Autoimmune disorders, blepharitis, scleritis, age-related macular degeneration (AMD), diabetic retinopathy (DR), diabetes Diabetic macular edema (DME), ocular neovascularization, age-related macular degeneration (ARMD), proliferative vitreoretinal PVR, cytomegalovirus (CMV) retinopathy, optic neuritis, retrobulbar neuritis, and In one embodiment, the macular pucker is one or more selected from the group consisting of: The eye disease is dry eye. In one embodiment, the eye disease is allergic conjunctivitis. In one embodiment, the eye disease is age-related macular degeneration (AMD). The eye disease is diabetic retinopathy. [Brief description of the drawings]
[0095] [Figure 1] 1 is a graph summarizing the results of a Schirmer study with vehicle, a formulation containing 0.05% by weight cyclosporine, and a formulation containing 0.09% by weight cyclosporine. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0096] Active Agent According to various aspects and embodiments of the methods and compositions provided herein, an active agent Agents that, when present in addition to cyclosporine, can affect biological processes It can be any drug. An active drug in addition to cyclosporine (the term active ingredient is used interchangeably with the term active Drugs (used interchangeably with drugs) include drugs, hormones, cytokines, toxins, therapeutic agents, and biologics. In some embodiments, the aspects and implementations disclosed herein include The active agent in the form can treat or prevent a disease or condition, and is an approved drug for that purpose, e.g., in some embodiments, the active drug The compound may be capable of treating or preventing an ocular disease or condition, or It has been approved for:
[0097] In some embodiments, the active agent in addition to cyclosporine is an antibiotic, e.g., Azithromycin, ciprofloxacin, ofloxacin, gatifloxacin, levofloxacin The group consisting of fluoxacin, moxifloxacin, besifloxacin, and levofloxacin In some embodiments, the active agent is one or more antibiotics selected from the group consisting of , antiviral agents, such as ganciclovir, trifluridine, acyclovir, famciclovir cyclovir, valacyclovir, penciclovir, and cidofovir. The antiviral agent or agents are
[0098] In some embodiments of any of the aspects and embodiments disclosed herein, the active The agent is cyclosporine A, an analog thereof, or a pharma- ceutically acceptable salt thereof.
[0099] It was originally extracted from the soil fungus Potypacaidium infilatum. Cyclosporines have a cyclic 11-amino acid structure, e.g., cyclosporines A to I Cyclosporines include, for example, cyclosporines A, B, C, D and G. Cyclosporines are used in immunotherapy. Binds to the cytoplasmic protein cyclophilin of responding lymphocytes, especially T-lymphocytes, forming a complex The complex induces the transcription of interleukin-2 (IL-2) under normal circumstances. Cyclosporine inhibits the production of lymphokines and interferons. It also inhibits leukin release, resulting in decreased effector T cell function.
[0100] eye disease In various aspects and embodiments, the formulations disclosed herein are useful for treating ophthalmic diseases or disorders. The present invention may be used to treat or prevent ocular diseases and disorders contemplated herein. In certain embodiments, the present invention provides a method for treating glaucoma, comprising administering to the patient an anterior or posterior disease. Exemplary ocular diseases that may be treated with the formulations as indicated include the following:
[0101] Dry Eye Syndrome (DES, chronic dry eye, keratitis sicca; xerophthalmia; keratoconjunctivitis sicca) ) is a condition caused by a variety of disorders that result in the loss of, or a change in the composition of, the natural tear film that maintains the ocular surface. Without the tear film, vision is impaired and the patient experiences severe eye discomfort. DES can be caused by excessive tear evaporation or increased tear production in the lacrimal gland, which is the site of tear production. The exact cause of this condition is unknown and may be caused by a decrease in tear production. There is evidence supporting an association between a decrease in lacrimal duct size and inflammation of one or more components of the lacrimal apparatus. Currently available drug therapies for DES have led to the development of more effective and better tolerated products. There is room for quality.
[0102] DES also causes Shag syndrome, an autoimmune disorder in which the glands that produce tears and saliva are destroyed. It may also be a manifestation of Ren's syndrome, which is characterized by dry mouth, decreased tear production, and other dry mucous membranes. results.
[0103] Non-infectious uveitis is a chronic inflammatory, putative Th1 / It is a Th17-mediated autoimmune disease and is potentially blinding. Blindness from uveitis can occur in does not usually result from a single inflammatory episode; rather, cumulative damage occurs in recurrent episodes of inflammation. Inflammatory sequelae leading to blindness include cystoid macular edema, cataracts, vitreous debris, These conditions include one or more of the following: glaucoma, macular lesions (scarring and atrophy), optic neuropathy, and retinal detachment. It is okay to be swallowed.
[0104] Anterior uveitis (iritis) occurs in the front of the eye and is the most common form of uveitis. Pars planitis is inflammation of the pars plana, a narrow area between the iris and the choroid. This condition occurs more frequently in young men and is not usually accompanied by another disease. Chondroitis is an inflammation of the uveal tract, mainly the choroid. It affects the posterior portion. If the retina is also involved, it is called chorioretinitis. Uveitis can occur in association with autoimmune diseases or secondary to a systemic infection. In peripheral uveitis, inflammation can last for months to years and, even with treatment, may not result in permanent vision loss. May cause injury.
[0105] Uveitis can cause blurred vision, eye pain, and vision loss. Approximately 10% of new cases of glaucoma are caused by uveitis. 1,000 people suffer from uveitis in the United States alone, the majority of whom are affected by anterior uveitis. The only therapeutic class approved by the FDA for the treatment of uveitis is colposcopy. It is a steroid that has multiple side effects, such as hypertension, hyperglycemia, and hypercholesterolemia. It has been noted in sterolemia and in the eye, in glaucoma and cataract formation.
[0106] Pink eye lines the eyelids and covers exposed areas of the sclera, or white of the eye. It refers to a group of diseases that cause swelling, itching, burning, and redness of the protective membrane of the conjunctiva.
[0107] Keratitis is an inflammation of the cornea (the clear part at the front of the eye). Keratitis can be caused by infection (bacterial, fungi, viruses, parasites, etc.) or non-infectious agents (e.g. , Certain types of autoimmune diseases are associated with a variety of non-infectious keratitis.
[0108] Keratoconjunctivitis refers to inflammation of the cornea and conjunctiva.
[0109] Vernal keratoconjunctivitis (VKC) is a recurrent condition characterized by hard, elevated, cobblestone-like bumps on the upper eyelid. It is an inflammatory disease of the eye. There may also be swelling and thickening of the conjunctiva. The conjunctiva is only located on the eyelids, not the cornea. It is also the outermost membrane that lines the exposed parts of the eye.
[0110] Atopic keratoconjunctivitis is the result of a condition called atopy, which is when the immune system It is a genetic condition that results in the production of higher than normal levels of antibodies in response to a given allergen.
[0111] Systemic immune-mediated diseases, such as cicatricial conjunctivitis, and other autoimmune disorders of the ocular surface, can develop acutely. A clinically heterogeneous group of conditions in which chronic and autoreactive mechanisms can cause substantial damage to the eye. When severe and affecting the conjunctival epithelium and stroma, scarring may ensue. These conditions are generally rare and result in considerable mechanical changes. However, it can cause significant pathology and visual impairment.
[0112] Blepharitis is a common condition that causes inflammation of the eyelids.
[0113] Scleritis is a serious inflammatory disease that affects the white, outer membrane of the eye, known as the sclera.
[0114] Age-related macular degeneration (AMD) is an age-related disease that gradually destroys sharp central vision. AMD affects the macula, which is located in the center of the retina. AMD can be classified as wet or dry. It occurs in two forms. In wet AMD, abnormal blood vessels behind the retina begin to grow under the macula. These new blood vessels tend to be very fragile and often block blood and fluids. Blood and fluid elevate the macula from its normal position at the back of the eye. Damage to the macula occurs rapidly. Dry AMD is caused by the slow destruction of light-sensitive cells in the macula. This occurs when the eye is opened and causes a gradual blurring of central vision in the affected eye.
[0115] Diabetes can affect the eye in several ways. Diabetic retinopathy (DR) is a condition that affects the fundus ( It is a complication of diabetes caused by damage to the blood vessels in the light-sensitive tissue of the retina. Diabetic retinopathy may not cause any symptoms at all or may just cause mild vision problems. However, ultimately, diabetic retinopathy can lead to blindness. Diabetic macular edema (DME) is a condition caused by leakage of fluid from blood vessels in the macula in diabetes. It is swelling of the retina.
[0116] Ocular neovascularization is the abnormal or excessive formation of blood vessels in the eye. It has been demonstrated in diabetic retinopathy and age-related macular degeneration (AMD).
[0117] Proliferative vitreoretinopathy (PVR) is the formation of scar tissue inside the eye. Cells grow and multiply. and "vitreoretinopathy" because the problem involves the vitreous and retina. In PVR, scar tissue forms in sheets over the shrinking retina. This marked shrinkage PVR pulls the retina towards the center of the eye, severely detaching and distorting the retina. This can occur both posteriorly and anteriorly with folding of the retina in both the posterior and circumferential directions.
[0118] Cytomegalovirus (CMV) is related to the herpes virus and is present in most people. The human immune system is damaged due to disease (HIV), organ or bone marrow transplants, or chemotherapy. When the CMV virus is kept in check by the immune system, it can cause damage and infection in the eyes and other parts of the body. CMV accounts for approximately 30% of cases by causing damage to the retina. 0% of cases affect the eyes, which is called CMV retinopathy.
[0119] Optic neuritis occurs when the optic nerve becomes inflamed and the myelin sheath becomes damaged or destroyed. Nerve damage that occurs in the part of the optic nerve that is located behind the eye is called retrobulbar neuritis. , which is another term sometimes used for optic neuritis.
[0120] Epiretinal membranes, also known as macular pucker, are scar tissue-like membranes that form over the macula. It typically progresses slowly and causes blurring and distortion. It affects central vision. As it progresses, the pulling of the membrane over the macula causes swelling. This can cause problems.
[0121] In certain embodiments, the composition is used to treat, for example, graft rejection of a corneal allograft following transplantation. In inflammation, T lymphocytes mediate the rejection of foreign tissue. It is well known that prevention of rejection plays a crucial role in the survival of transplant recipients. The rejection reaction is most important in maintaining the health of the cornea after transplantation. This can occur in either the stroma or the layers that make up the corneal endothelium. The endothelial layer helps to keep the cornea compact. It acts as a pump by removing water from the corneal stroma. When the collagen fibers are damaged, the collagen fibers become disoriented and the cornea loses transparency. Human endothelial cells are non-replicative and, as a result, do not contribute to donor proliferation in the setting of rejection. Cell loss is irreversible and can lead to reduced graft function and survival. The goal of either preventing or treating rejection in corneal transplant recipients is to increase the endothelial cell The disclosed compositions are intended to prevent and minimize corneal allograft rejection following corneal allograft transplantation. It can be used to prevent.
[0122] Additional formulation ingredients The compositions of the present disclosure may also contain other ingredients, such as, but not limited to, additives, adjuvants, buffers, , an isotonicity agent, a bioadhesive polymer, and a preservative. In any of the compositions of the present disclosure, the mixture is preferably formulated at about pH 5 to about pH 8. This pH range can be adjusted by adding a buffer to the composition, as described in the Examples. In one embodiment, the pH range of the composition in the formulation may be about pH 6. The compositions of the present disclosure may be used in any common buffer system, such as phosphate buffer, ... Salts, borates, acetates, citrates, carbonates, and borate-polyol complexes. The pH and osmolality may be adjusted to appropriate physiological values by well-known techniques. It will be understood that the mixed micelle compositions of the present disclosure are stable in aqueous buffer solutions. That is, there may be incompatible interactions between the buffer and any other components that would cause the composition to be unstable. There is no interaction at all.
[0123] Examples of isotonicity agents include mannitol, sodium chloride, sodium nitrate, sodium sulfate, etc. These are isotonic sugars, dextrose, xylitol, or combinations thereof. The tonicity agent may be used to adjust the osmolarity of the composition. The osmolarity is adjusted to be in the range of about 250 to about 350 mOsmol / kg. In a preferred embodiment, the osmolarity of the formulation is adjusted to about 280 to about 300 mOsmol / kg. will be done.
[0124] Additives, such as sugars, glycerol, and other sugar alcohols, may be included in the compositions of the present disclosure. Pharmaceutical excipients are used to enhance the efficacy or potency of other ingredients in the composition. For example, pharmaceutical excipients may be added to improve the stability of calcineurin inhibitors. To adjust the osmolality of the composition, to adjust the viscosity of the composition, or to provide another For this reason, for example, to effect drug delivery, the compositions of the present disclosure may be added to the compositions of the present disclosure. Non-limiting examples of pharmaceutical excipients include sugars, e.g., trehalose, mannose, D-galactose, In certain embodiments, the sugar is added prior to hydration of the film. In another embodiment, the sugar can be incorporated into the composition (i.e., internally). can be incorporated into the composition (i.e., externally) during the hydration process. In an embodiment, the aqueous clear mixed micellar solution of the present disclosure includes an additive, such as a sugar.
[0125] In certain embodiments, the compositions of the present disclosure further comprise one or more bioadhesive polymers. Bioadhesion includes the binding of certain synthetic and biological macromolecules and hydrocolloids. Bioadhesion refers to the ability of a polymer to adhere to biological tissue. It depends in part on the biological tissue and the surrounding environment. Several factors, namely hydrogen The presence of functional groups capable of forming crosslinks (-OH, COOH), the presence of anionic charges The polymer chains must have sufficient elasticity to allow the mucus layer to interpenetrate, and high It was found that molecular weight contributes to the bioadhesive ability of the polymer. It has been used in surgery, ophthalmology, and other surgical applications, but more recently in other areas. The use of bioadhesive materials for, e.g., soft tissue-based artificial substitutes, and localization of bioactive agents. There has been considerable interest in controlled release systems for the release of drugs from the mouth or throat. include systems for release of drugs in the nasal cavity and for enteral or rectal administration.
[0126] In certain embodiments, the compositions of the present disclosure include at least one bioadhesive polymer. The bioadhesive polymer increases the viscosity of the composition, thereby increasing its residence time in the eye. Bioadhesive polymers of the present disclosure include, for example, Carbopol ( Carbomer, Noveon® (polycarbophil), etc. Carboxylic acid polymers, methylcellulose, hydroxypropylcellulose, carboxymethylcellulose Cellulosic derivatives, including alkyl and hydroxyalkyl celluloses such as cellulose acetate Conductive, gums such as locust bean, xanthan, agarose, karaya, guar, etc. and, but not limited to, polyvinyl alcohol, povidone, polyethylene glycol, P luronic® (poloxamer), tragacanth, and hyaluronic acid; ophthalmic Phase transition polymers (e.g., arsenic) to provide sustained and controlled delivery of encapsulated drugs into the glycerin, carrageenan (e.g., Eucheuma, xanthan and Locust bean gum mixture, pectin, cellulose acetate phthalate, alkyl hydroxy Alkyl cellulose and its derivatives, hydroxyalkylated polyacrylic acid and its derivatives These include other polymers including poloxamers and their derivatives. The physical characteristics of the polymer may be affected by environmental factors, such as ions, either alone or in combination with other factors. The change may be mediated by changes in acid strength, pH, or temperature. The optional bioadhesive polymer or polymers may be present in an amount of from about 0.01% to about 10% by weight / In one embodiment, the composition is present in an amount of about 0.1 to about 5% by weight per volume. The composition of the present disclosure may be, for example, PVP-K-30, PVP-K-90, HPMC, H At least one hydrophilic polymer excipient selected from EC and polycarbophil In one embodiment, the polymer excipient further comprises PVP-K-90, PVP-K In one embodiment, the polymer excipient is selected from P-30, or HPMC. It is selected from VP-K-90 or PVP-K-30.
[0127] In certain embodiments, if a preservative is desired, the composition may contain benzyl EDTA or EDTA-free preservatives. Alcohol, Benzalkonium Chloride, Chlorhexidine, Cosmocil® , CQ, or Dowicil® 200. In certain embodiments, the methods described herein may be optionally stored in It may be desirable for the formulation as described above to be free of any preservatives. In some embodiments, it may be desirable, even if not necessary, in a formulation contained in a single-use container. In other embodiments, for example, the formulation may be contained in a multi-use container. In certain embodiments, it may be advantageous to include a preservative.
[0128] The ophthalmic composition is administered topically to the eye as a biocompatible, aqueous, clear mixed micellar solution. The composition may be incorporated into micelles that are dispersed in an aqueous medium and / or or has an encapsulated drug.
[0129] Non-Limiting List of Exemplary Embodiments In addition to the aspects and embodiments described and provided elsewhere in this disclosure, the following A non-limiting list of specific embodiments is specifically contemplated. 1. 0.087-0.093% by weight of cyclosporine, polyoxyl lipid or fatty acid and a polyalkoxylated alcohol. 2. 0.087-0.093% by weight of cyclosporine and polyoxyl of n≧40 An ophthalmic preparation comprising a lipid or a fatty acid. 3. 0.087-0.093% by weight of cyclosporine and polyoxyl lipid or An ophthalmic formulation comprising a fatty acid, wherein the polyoxyl lipid or fatty acid is at least 0.05% by weight of the formulation. Present in an amount equal to or greater than .5% in the formulation. 4. 0.087-0.093% by weight of cyclosporine and polyoxyl lipid or 1. An ophthalmic formulation comprising a fatty acid, the formulation comprising nanomicelles. 5. 0.087-0.093% by weight cyclosporine, 0.5-5% HCO-40 , HCO-60, HCO-80, and HCO-100 or more, and about 0.01 to 0.1% octoxynol-40. . 6. 0.087-0.093% by weight cyclosporine, 0.6-2% HCO-40 , HCO-60, HCO-80, and HCO-100 or more, and about 0.02 to 0.1% octoxynol-40. . 7. Cyclosporine at about 0.09%, HCO-40 at 0.5-5%, HCO-60 at 0.5-5%, HCO-80, and HCO-100; and 1. An ophthalmic preparation comprising about 0.02 to 0.1% octoxynol-40. 8. 0.087-0.093% by weight cyclosporine, 0.6-4% HCO-40 , HCO-60, HCO-80, and HCO-100 or multiple polyoxyl lipids, and about 0.02 to 0.1% octoxynol-40 1. An ophthalmic formulation comprising: 9. 0.087-0.093% by weight of cyclosporine, 0.7-4% of polyoxyethylene and about 0.02 to 0.1% octoxynol-40. formulation. 10. 0.087-0.093% by weight cyclosporine, 0.8-4% polyoxyl lipids or fatty acids; and about 0.02 to 0.1% octoxynol-40 A formulation comprising nanomicelles. 11. 0.087-0.093% by weight cyclosporine, 0.9-4% polyoxyl lipids or fatty acids; and about 0.02 to 0.1% octoxynol-40 A formulation comprising nanomicelles. 12. 0.087-0.093% by weight of cyclosporine, about 1% of HCO-40, H one selected from the group consisting of CO-60, HCO-80, and HCO-100; and about 0.02-0.1% Octoxynol-40. 13. 0.087-0.093% by weight of cyclosporine, about 1% of HCO-60, and and about 0.02-0.1% Octoxynol 40. 14. 0.087-0.093% by weight cyclosporine, 0.5-4% HCO-4 0, HCO-60, HCO-80, and HCO-100 or more, and about 0.05% Octoxynol-40. 15. 0.087-0.093% by weight cyclosporine, 0.5-4% HCO-4 0, HCO-60, HCO-80, and HCO-100 or more, and about 0.01% Octoxynol-40. 16. Cyclosporine at about 0.09%, HCO-40 at 0.5-4%, HCO-60 , HCO-80, and HCO-100; and about 0.05% Octoxynol-40. 17. 0.087-0.093% by weight cyclosporine, 0.6-2% HCO-4 0, HCO-60, HCO-80, and HCO-100 or a plurality of polyoxyl lipids, and about 0.05% octoxynol-40 , ophthalmic preparations. 18. 0.087-0.093% by weight cyclosporine, 0.6-2% polyoxyl 1. An ophthalmic preparation comprising: a lipid or fatty acid; and about 0.05% octoxynol-40. 19. 0.087-0.093% by weight cyclosporine, 0.6-2% polyoxyl A lipid or fatty acid; and about 0.05% octoxynol-40. A formulation comprising nanomicelles. 20. 0.087-0.093% by weight cyclosporine, 0.6-2% polyoxyl A lipid or fatty acid; and about 0.05% octoxynol-40. A formulation comprising nanomicelles. 21. 0.087-0.093% by weight of cyclosporine, about 1% of HCO-40, H one selected from the group consisting of CO-60, HCO-80, and HCO-100; and about 0.05% Octoxynol-40. 22. 0.087-0.093% by weight of cyclosporine, about 1% of HCO-60, and and about 0.05% Octoxynol 40. 23. The polyoxyl lipid or fatty acid is 0.6 to 2% by weight of the preparation. The formulation according to any one of the embodiments. 24. The above-mentioned polyoxyl lipid or fatty acid is 0.8 to 2% by weight of the above-mentioned preparation. The formulation according to any one of the embodiments. 25. The polyoxyl lipid or fatty acid is 0.9 to 1.5% by weight of the formulation. , the formulation of any of the preceding embodiments. 26. The above-mentioned polyoxyl lipid or fatty acid is 1 to 1.5% by weight of the above-mentioned preparation. The formulation according to any one of the embodiments. 27. The above-mentioned polyoxyl lipid or fatty acid is 0.5 to 5% by weight of the above-mentioned preparation. The formulation according to any one of the embodiments. 28. The polyoxyl lipid or fatty acid is 0.6 to 5% by weight of the preparation. The formulation according to any one of the embodiments. 29. The polyoxyl lipid or fatty acid is 0.6 to 4% by weight of the preparation. The formulation according to any one of the embodiments. 30. The polyoxyl lipid or fatty acid is 0.6 to 3% by weight of the preparation. The formulation according to any one of the embodiments. 31. The above-mentioned polyoxyl lipid or fatty acid is 0.6 to 2% by weight of the above-mentioned preparation. The formulation according to any one of the embodiments. 32. The above-mentioned polyoxyl lipid or fatty acid is 0.6 to 1% by weight of the above-mentioned preparation. The formulation according to any one of the embodiments. 33. The above-mentioned polyoxyl lipid or fatty acid is 0.8 to 5% by weight of the above-mentioned preparation. The formulation according to any one of the embodiments. 34. The above-mentioned polyoxyl lipid or fatty acid is 0.8 to 4% by weight of the above-mentioned preparation. The formulation according to any one of the embodiments. 35. The above-mentioned polyoxyl lipid or fatty acid is 0.8 to 3% by weight of the above-mentioned preparation. The formulation according to any one of the embodiments. 36. The above-mentioned polyoxyl lipid or fatty acid is 0.8 to 2% by weight of the above-mentioned preparation. The formulation according to any one of the embodiments. 37. The above-mentioned polyoxyl lipid or fatty acid is 0.9 to 2% by weight of the above-mentioned preparation. The formulation according to any one of the embodiments. 38. The polyoxyl lipid or fatty acid is 0.9 to 1.5% by weight of the preparation. , the formulation of any of the preceding embodiments. 39. The method of any preceding claim, wherein the polyoxyl lipid or fatty acid is about 1% by weight of the formulation. The formulation according to any of the embodiments. 40. The method according to claim 1, wherein the polyoxyl lipid or fatty acid is greater than about 0.6% by weight of the formulation. The formulation according to any one of the embodiments. 41. The method according to claim 1, wherein the polyoxyl lipid or fatty acid is greater than about 0.7% by weight of the formulation. The formulation according to any one of the embodiments. 42. The method according to claim 1, wherein the polyoxyl lipid or fatty acid is greater than about 0.8% by weight of the formulation. The formulation according to any one of the embodiments. 43. The method according to claim 1, wherein the polyoxyl lipid or fatty acid is greater than about 0.9% by weight of the formulation. The formulation according to any one of the embodiments. 44. The method of any of the preceding claims, wherein the polyoxyl lipid or fatty acid is greater than about 1% by weight of the formulation. The formulation of any one of the embodiments. 45. When present, the polyalkoxylated alcohol comprises 0.005 to 1.0% of the formulation. The formulation of any of the preceding embodiments, wherein the formulation is 4% by weight. 46. When present, the polyalkoxylated alcohol comprises 0.005 to 1.0% of the formulation. The formulation of any of the preceding embodiments, wherein the formulation is 3% by weight. 47. When present, the polyalkoxylated alcohol comprises 0.005 to 1.0% of the formulation. The formulation of any of the preceding embodiments, wherein the formulation is 2% by weight. 48. When present, the polyalkoxylated alcohol comprises 0.005 to 1.0% of the formulation. The formulation of any of the preceding embodiments, wherein the formulation is 1% by weight. 49. When present, the polyalkoxylated alcohol comprises 0.005 to 1.0% of the formulation. The formulation of any of the preceding embodiments, wherein the formulation is 0.5% by weight. 50. When present, the polyalkoxylated alcohol comprises 0.005 to 1.0% of the formulation. The formulation of any of the preceding embodiments, wherein the formulation is 0.1% by weight. 51. When present, the polyalkoxylated alcohol comprises 0.005 to 1.0% of the formulation. The formulation of any of the preceding embodiments, wherein the formulation is 0.05% by weight. 52. When present, the polyalkoxylated alcohol comprises 0.008 to 1.0% by weight of the formulation. The formulation of any preceding embodiment, wherein the formulation is 0.02% by weight. 53. When present, the polyalkoxylated alcohol comprises about 0.05% by weight of the formulation. % by weight. 54. The method according to any one of the preceding claims, wherein the polyoxyl lipid or fatty acid is polyoxyl castor oil. The formulation according to any of the embodiments. 55. The polyoxyl lipid or fatty acid is HCO-60, HCO-80, or H As described in any of the preceding embodiments, wherein the one or more are selected from Formulation. 56. The preceding embodiment, wherein the polyoxyl lipid or fatty acid is HCO-60. The formulation according to any one of the preceding claims. 57. Any of the preceding embodiments, wherein the active agents include a combination of two different agents. The formulation described above. 58. The active agent is a resolvin or resolvin-like compound, a steroid (e.g., corticosteroids), cyclosporine A, and voclosporin The formulation of any of the preceding embodiments, comprising two or more active agents. 59. The method of any one of the preceding claims, wherein the active agents further include a resolvin and a corticosteroid. The formulation according to any of the embodiments. 60. The preceding method, wherein the active agents include cyclosporine A and corticosteroids. The formulation according to any of the embodiments. 61. The active agent is selected from the group consisting of resolvins, cyclosporine A, and corticosteroids. The formulation of any of the preceding embodiments, comprising 62. The formulation of any of the preceding embodiments, which does not contain a preservative. 63. Benzyl alcohol with or without EDTA, benzalkonium chloride, chlorhexidine Cosmocil®, CQ, or Dowicil® 200 The formulation of any of the preceding embodiments, wherein the formulation does not comprise 64. A method of treating or preventing an eye disease or condition, comprising administering to a subject a composition comprising any one of the preceding embodiments. The method comprises the step of topically administering the formulation described in any one of claims 1 to 4. 65. A method for treating or preventing an eye disease or condition, said method comprising the steps of: The method includes locally administering the formulation of any of the embodiments, wherein the disease is an anterior segment disease. ,method. 66. A method for treating or preventing an eye disease or condition, said method comprising the steps of: The method includes locally administering the formulation of any one of the embodiments, wherein the disease is a posterior disease. ,method. 67. A method for treating or preventing an eye disease or condition, said method comprising the steps of: The method comprises administering the formulation of any one of the embodiments to a patient having a dry eye syndrome. group, Sjogren's syndrome, uveitis, anterior uveitis (iritis), retinal chorioretinitis, posterior uveal tract inflammation Duodenal vein inflammation, conjunctivitis, allergic conjunctivitis, keratitis, keratoconjunctivitis, vernal keratoconjunctivitis (VKC), Topical keratoconjunctivitis, systemic immune-mediated diseases such as cicatricial conjunctivitis, and other autoimmune diseases of the ocular surface. Autoimmune disorders, blepharitis, scleritis, age-related macular degeneration (AMD), diabetic retinopathy (DR), diabetes Pathologic macular edema (DME), ocular neovascularization, age-related macular degeneration (ARMD), proliferative vitreoretinopathy (PVR), cytomegalovirus (CMV) retinopathy, optic neuritis, retrobulbar neuritis, and The method of claim 1, wherein the macular pucker is one or more selected from the group consisting of: 68. A method for treating or preventing an eye disease or condition, said method comprising the steps of: The method comprises administering the formulation of any one of the embodiments to a patient having a dry eye syndrome. A group, a method. 69. A method for treating or preventing an eye disease or condition, said method comprising the steps of: The method comprises topically administering the formulation of any one of the embodiments, wherein the disease is an allergic condition. Uveitis, method. 70. A method for treating or preventing an eye disease or condition, said method comprising the steps of: The method includes locally administering the formulation according to any one of the embodiments, wherein the disease is age-related macular degeneration ( AMD).
[0130] The following examples are provided to further illustrate aspects of the present invention. , are non-limiting and should not be construed as limiting any aspect of the invention. EXAMPLES
[0131] Preparation of mixed nanomicelle cyclosporine-containing formulation The mixed nanomicelle formulation cyclosporine is prepared as follows: Hydrogenated 40 polyoxyl castor oil is melted, Slowly add cyclosporine thereto, and then substantially homogenize the ingredients. Octoxynol 40 was added to the resulting homogenous mixture and stirred until substantially homogenous. ,after that, Add excipients (e.g., sodium phosphate) with sufficient stirring to achieve good dissolution of each. sodium phosphate monobasic, sodium phosphate dibasic, and sodium chloride) are added separately. .
[0132] The prepared formulations were subjected to various tests, e.g., encapsulation efficiency, loading efficiency, mixed nanomicelle size, , and polydispersity index.
[0133] Mixed nanomicelle size and polydispersity index: The formulation size and polydispersity index were determined by Zet asizer, Malvern Instrument, NJ. Approximately 1 ml of each formulation was transferred into a cuvette and placed in the instrument. Light was used to determine the mixed nanomicelle size. The nanomicelles contemplated in this disclosure are approximately having a particle size in the range of 1 to 100 nm; in some embodiments, the particle size is about in some embodiments, the particle size is in the range of about 10 to 40 nm. in some embodiments, the particle size is about 15 nm.
[0134] Encapsulation efficiency: To determine the encapsulation efficiency of the formulations, all the prepared formulations were subjected to an encapsulation efficiency test. Briefly, the formulations were vortex mixed for homogeneity and 1 mL was added to fresh (1 Each formulation was lyophilized and transferred to an Eppendorf tube (0.5 mL). Obtain a solid at the bottom of the Dolph tube. Add 1 mL of the obtained solid to an organic solvent (diethyl ether) and The drug is suspended in an organic solvent to form reverse micelles, releasing the drug into the external organic solvent. The solvent is evaporated overnight in a speed vacuum. The resulting reverse micelles are dissolved in 1 mL of 2-propanol. They were then resuspended (taking into account the dilution factor) and further diluted to separate the individual micelles by HPLC. The concentration of cyclosporine entrapped in the formulation is determined. The entrapment efficiency of the formulation is calculated using the following formula: Calculate (where MNF = mixed nanomicelle formulation): Encapsulation efficiency = (amount of drug quantified in MNF) / amount of drug added to MNF × 10 0
[0135] Drug quantification by HPLC: In vitro analysis of cyclosporine by Shimadzu HPLC pump (Shimadzu, Shimadzu Scientific in instrument, Columbia, MD), Alcott autosampler (model 7 18AL), Shimadzu UV / Visible Detector (Shimadzu, SPD-20A / 20AV, USA), an ODS column (5 μm) thermostatted at 40 ± 1 °C. , 150 × 4.6 mm), and a Hewlett Packard HPLC integrator (H Reversed-phase high-performance liquid chromatography (Research Institute, New Hampshire, NY) was used. The analysis was performed by RP-HPLC. The mobile phase was methanol (MeOH ), water and trifluoroacetic acid (TFA) (70:30:0.05% v / v); It is set to a flow rate of 0.5 mL / min. The detection wavelength is set to 272 nm. The tray temperature is maintained at 4°C. Calibration curve for cyclosporine (0.5-5 μg / mL) is prepared by making appropriate dilutions from the stock solution in 2-propanol. An injection volume of 100 μl is injected onto the HPLC column for analysis. The samples are then stored at 4° C. before and between analyses. EXAMPLES
[0136] Preparation of mixed nanomicelle cyclosporine-containing formulations using solvent-based or melt-based methods preparation The mixed nanomicelle formulations encapsulating cyclosporine were prepared by a solvent evaporation method in two steps. R: compounding the bulk ophthalmic solution; and Filling bulk ophthalmic solutions into form-fill-synthetic (BFS) unit doses and then packaging them in individual foils Packaging 4 BFS unit strips in pouches.
[0137] An exemplary solvent-based manufacturing process contemplated for use herein is as follows: Please provide more details: Step 1: The required amounts of cyclosporine, octoxynol-40, and HCO-40 are added to the eluate. Dissolve the mixture in ethanol and place in a suitable sized round bottom flask. Attach the flask to the rotor and begin rotation to mix the contents of the flask. Step 2: Remove the ethanol by rotary evaporation until a thin film is obtained. Step 3: Add the required amount of water for injection to the flask containing the membrane from step 2 and circulate the contents. Dissolution is achieved by laminar mixing. Step 4: Add the required amount of sodium chloride and pre-prepared phosphate buffer to a stainless steel Add the mixture to a plastic container and mix the contents. Step 5: Transfer the contents from step 3 to the tank containing the buffer and stir until dissolved. do. Step 6: Add the required amount of povidone to the tank and stir until dissolved. Step 7: Measure and adjust (if necessary) the pH of the solution in step 6 and add water for injection to make a final solution. Convert to volume. Step 8: The solution from step 7 is sterile filtered and dispensed into form-fill-synthetic (BFS) unit dose vials. Aseptically fill into tubes with a nominal fill volume of 0.25 mL. Step 9: Package the vials in heat sealed foil pouches in strips of 4 BFS units.
[0138] An exemplary melt-based manufacturing process contemplated for use herein is as follows: Please provide more details: Step 1: Dissolve the required amount of HCO-40 in a flask heated to about 60°C with stirring. When liquefied, add the required amount of cyclosporine and mix until dissolved. The Octoxynol-40 is then added and the entire solution is mixed until uniform. Step 2: Add the required amount of water for injection into a stainless steel container and stir until the temperature reaches 25°C. Mix. Step 3: Transfer the contents from step 1 to a stainless steel container and stir until dissolved. Step 4: Add the required amount of sodium chloride and phosphate buffer to a stainless steel vessel; The contents are mixed until dissolved. Step 5: Add the required amount of povidone to the container and stir until dissolved. Step 6: Measure and adjust (if necessary) the pH of the solution in step 5 and add water for injection to make a final solution. Convert to volume. Step 7: The solution from step 6 is sterile filtered and dispensed into form-fill-synthetic (BFS) unit dose vials. Aseptically fill into tubes with a nominal fill volume of 0.3 mL. Step 8: The vials are packaged in 4 BFS unit strips in heat sealed foil pouches. EXAMPLES
[0139] Preparation of mixed nanomicellar cyclosporine-containing formulations using ethanol solvent evaporation method The mixed nanomicelle formulations encapsulating cyclosporine were prepared by a solvent evaporation method in two steps. R: compounding the bulk ophthalmic solution; and Filling bulk ophthalmic solutions into form-fill-synthetic (BFS) unit doses and then packaging them in individual foils Packaging 4 BFS unit strips in pouches.
[0140] The manufacturing method used herein is described in more detail as follows: Step 1: Add the required amount of cyclosporine, octoxynol-40, and vitamin E amber. Dissolve the acid polyethylene glycol in ethanol and place in a suitable sized round bottom flask. Place the flask on a rotary evaporator and start the rotation to mix the contents of the flask. Combine. Step 2: Remove the ethanol by rotary evaporation until a waxy solid is obtained. Step 3: Add the required amount of water for injection to the flask containing the waxy residue from step 2. The contents are then dissolved by rotary (laminar) mixing. Step 4: The contents from step 3 are poured into a stainless steel vessel containing the required amount of povidone solution. Transfer to a bowl and mix contents until uniform. Step 5: Add the required amount of sodium chloride and pre-prepared phosphate buffer in step 4. Add the mixture to the solution and mix the contents. Step 6: Measure and adjust (if necessary) the pH of the solution in step 5 and add water for injection to make a final solution. Convert to volume. Step 7: The solution from step 6 is sterile filtered and dispensed into form-fill-synthetic (BFS) unit dose vials. Aseptically fill into tubes with a nominal fill volume of 0.25 mL. Step 8: Package the vials in heat sealed foil pouches in 4 BFS unit strips. EXAMPLES
[0141] Preparation of mixed nanomicellar cyclosporine-containing formulations using alternative sequences of additive melt-based methods Manufacturing Step 1: Dissolve the required amount of HCO-40 in a flask heated to about 60°C with stirring. Once liquefied, add the required amount of cyclosporine and mix until dissolved and homogenous. Mix. Step 2: The required amount of Octoxynol-40 is heated to about 60°C and liquefied to form Cyclo Add to the Asporin HCO-40 mixture. Step 3: Add the required amount of water for injection at about 25° C. to the flask containing the dissolved cyclosporine. Add to and stir until dissolved. Step 4: Add the required amount of sodium chloride and phosphate buffer to the flask and dilute the contents. Mix the above. Step 5: Weigh out the PVP-K90 and add to the solution and mix until dissolved. Step 6: Measure and adjust (if necessary) the pH of the solution in step 5 and add water for injection to make a final solution. Convert to volume. EXAMPLES
[0142] Any of the protocols described herein can be carried out with the following reagents: 0.09% by weight of cyclosporine, 1.0% by weight of hydrogenated 40 polyoxyl castor oil, and 0.05% by weight of Octoxynol-40 (Igepal); 0.405% by weight sodium phosphate monobasic, and optionally, 0.465% by weight sodium phosphate dibasic, 0.05% by weight of sodium chloride, 0.3% by weight of Povidone K90, and Water for injection.
[0143] A randomized, multicenter, double-blind, vehicle-controlled, dose-ranging study was designed to OTX-101 ophthalmic versus vehicle in approximately 420 subjects with keratoconjunctivitis sicca (KCS) Two concentrations of the solution were evaluated: 0.09% and 0.05%. Criteria (patient-reported history of KCS for ≥6 months, clinical diagnosis of bilateral KCS, score ≥3–9) The following Lissamine green staining scores and the modified Dry Eye Symptom Assessment (SA Subjects with a general symptom score of 40 or more based on the NDE questionnaire were randomly assigned to receive 1 x 100 mg / kg of ... They participated in a run-on period with vehicle administered topically twice daily (BID) for 14 days. After run-in, Lissamine green staining score and global symptom score in at least one eye Subjects who continued to meet the inclusion criteria were randomized to one of three treatment arms and followed for 12 weeks (84 days). Treatment received between: OTX-101 0.05% 1 drop in both eyes BID OTX-101 0.09% 1 drop in both eyes BID, and Vehicle 1 drop in both eyes, BID.
[0144] Subject symptoms were assessed using the SANDE questionnaire, and subject signs were assessed using Lissamine green conjunctival smear. staining, corneal fluorescein staining, Schirmer test (without anesthesia), and tear break-off time Safety was assessed using a 5-point ordinal scale. len visual acuity (VA), slit lamp examination, intraocular pressure (IOP) measurement, dilated ophthalmoscopy Safety and efficacy were assessed by ophthalmoscopy / fundus examination, collection of adverse events (AEs), and review of concomitant medications. and efficacy assessments were performed at study visits on days 14, 28, 42, 56, and 84. was assessed at each visit.
[0145] The results are shown in FIG. 1, where a formulation according to the present disclosure (containing 0.09% by weight cyclosporine) ) compared with placebo or a formulation containing only 0.05% cyclosporine by weight It turns out to be substantially more effective.
[0146] A formulation according to the present disclosure containing 0.09% by weight cyclosporine was Not only was such a formulation superior to vehicle in terms of Conjunctival staining (co-primary, p=0.008) and corneal It was also superior to the vehicle in terms of staining (p<0.001). % cyclosporine by weight) demonstrated clinically meaningful improvements in tear production in subjects Schirmer test scores from baseline based on data for both eyes are shown. The increase was more than 10 mm.
[0147] The invention illustratively described herein is not intended to be limited to any compound not specifically disclosed herein. In the absence of any element or elements, limitation or limitations The terms and expressions which have been used are words of description and not of limitation. and in the use of such terms and expressions, It is not intended to exclude any equivalents of the disclosed features or portions thereof, but various modifications may be made without departing from the spirit and scope of the invention. It is understood that this is possible within the scope of the invention as claimed. Although the present invention has been specifically disclosed by way of certain preferred embodiments and best features, the present invention is not limited to the disclosed embodiments. It is understood that modifications and variations of the concept may be resorted to by those skilled in the art, and that such modifications and variations are within the scope of the present invention. Such modifications and variations are within the scope of the invention as defined by the appended claims. It should be understood that it is considered to be.
[0148] The articles, patents, and patent applications, and other documents and publications mentioned or cited herein The contents of all information available electronically and in the electronic version are presented as if each separate publication were incorporated by reference. All such claims and any other related claims are hereby incorporated by reference in their entirety to the same extent as if specifically and individually indicated to be incorporated by reference in their entirety. The applicants hereby incorporate by reference any such articles, Physically transfer any and all of the materials and information from any patent, patent application, or other document reserves the right to incorporate it into its website.
[0149] The invention illustratively described herein is not intended to be limited to any compound not specifically disclosed herein. In the absence of any element or elements, limitation or limitations This may be implemented as appropriate. Thus, for example, the term "comprising" "Including" and "containing" are used to expand the scope of Further, the terms and expressions used herein are intended to be interpreted as meaningless. The terms are used herein as descriptive and not limiting terms, and as such In the use of words and expressions, any equivalent of the features shown and described, or However, various modifications are possible within the scope of the invention as claimed. It is understood, therefore, that the present invention is described in terms of preferred embodiments and best features. Although specifically disclosed, modifications and variations of the invention embodied therein are within the scope of the present invention. It is understood that modifications and variations may occur to those skilled in the art and that such modifications and variations are within the scope of the present invention. It should be understood that is considered within the scope of the present invention.
[0150] Although the invention has been described broadly and generically herein, it is to be understood that the invention is not limited to the specific embodiments described herein. Each of the narrower species and subgeneric groupings also form part of the invention. Any material from the generic concept may be included, regardless of whether the material is specifically recited in this specification. It also includes a generic description of the invention, with any proviso or negative limitation excluding any subject matter.
[0151] Furthermore, where features or aspects of the invention are described in terms of Markush groups, those skilled in the art will recognize that The person making the claim also has the right to make a claim with respect to any individual member or subgroup of members of the Markush group. I understand that this is what is stated here.
[0152] Other embodiments are within the scope of the following claims.
Claims
1. 0.087 to 0.093% by weight of cyclosporine, about 1.0% by weight of a polyoxyl lipid or fatty acid selected from HCO-40, HCO-60, HCO-80, HCO-100, or a combination thereof; and About 0.05% by weight of a polyalkoxylated alcohol A topical ophthalmic formulation comprising: the pH of the formulation is from about 5 to about 8; the formulation comprises mixed nanomicelles having a particle size of about 5 to about 50 nm; The cyclosporine is encapsulated in the core of the mixed nanomicelle. Ophthalmic topical preparations.
2. 2. The topical ophthalmic formulation of claim 1, wherein the polyoxyl lipid or fatty acid is hydrogenated 40 polyoxyl castor oil.
3. 2. The topical ophthalmic formulation of claim 1, wherein the polyalkoxylated alcohol is octoxynol-40.
4. 10. The topical ophthalmic formulation of claim 1, further comprising an additive, an adjuvant, a buffer, a tonicity agent, a bioadhesive polymer, a preservative, or a combination thereof.
5. 10. The topical ophthalmic formulation of claim 1, further comprising a buffering agent, a tonicity agent, and a bioadhesive polymer.
6. 6. The topical ophthalmic formulation of claim 5, which is free of organic solvents and / or preservatives.
7. 7. The topical ophthalmic formulation of any one of claims 4 to 6, wherein the buffer comprises a phosphate buffer, the tonicity agent comprises sodium chloride, and the bioadhesive polymer comprises povidone.
8. 10. The topical ophthalmic formulation of claim 1 having a pH of about 6.6 to about 7.
9. 2. The topical ophthalmic formulation of claim 1, wherein the mixed nanomicelles have a particle size of about 10 to about 40 nm.
10. 2. The topical ophthalmic formulation of claim 1, wherein the mixed nanomicelles have a particle size of about 15 nm.
11. A topical ophthalmic formulation according to any one of claims 1 to 10 for use in the treatment or prevention of an ophthalmic disease or condition.
12. 12. The topical ophthalmic formulation of claim 11, wherein the ophthalmic disease or condition is keratoconjunctivitis sicca.
13. 11. The topical ophthalmic formulation of any one of claims 1 to 10 for use in increasing tear production in a subject.
14. 14. The topical ophthalmic formulation of claim 13, wherein tear production is measured by Schirmer test score from baseline.
15. 15. The topical ophthalmic formulation of claim 14, which produces an increase in Schirmer test score from baseline of 10 mm or more in a subject.
16. 1. A topical ophthalmic formulation for treating an ocular inflammatory disease in a subject, the formulation comprising 0.09% by weight cyclosporine, hydrogenated 40 polyoxyl castor oil, and a polyalkoxylated alcohol, the pH of the formulation being from about 5 to about 8; The subject is i) A history of keratoconjunctivitis sicca (KCS) for at least 6 months; ii) clinical diagnosis of bilateral KCS; iii) a Lissamine Green staining score of about 3 to about 9; and iv) A global symptom score of about 40 or greater based on the modified "Symptom Evaluation in Dry Eye" (SANDE) questionnaire. having A topical ophthalmic formulation that provides a clinically significant improvement in tear production in both eyes that is an increase of 10 mm or more in Schirmer test score from baseline when the formulation is administered to the subject twice daily for at least two weeks.
17. 17. The topical ophthalmic formulation of claim 16, wherein administration of the formulation has about a 17.9% chance of achieving an increase in Schirmer test score from baseline of 10 mm or more in both eyes.
18. 17. The topical ophthalmic formulation of claim 16, wherein administration of the formulation results in about a 4.6% improvement in a subject's Schirmer test score compared to administration of an identical formulation except that it contains 0.05% by weight cyclosporine.
19. 17. The topical ophthalmic formulation of claim 16, wherein administration of the formulation results in about a 10.3% improvement in a subject's Schirmer test score compared to administration of an identical formulation but without cyclosporine.
20. The topical ophthalmic formulation of any one of claims 16 to 19, wherein the ocular inflammatory disease is keratoconjunctivitis sicca.
21. 20. The topical ophthalmic formulation of any one of claims 16 to 19, wherein the hydrogenated 40 polyoxyl castor oil is about 1.0% by weight of the formulation.
22. 20. The topical ophthalmic formulation of any one of claims 16 to 19, wherein the polyalkoxylated alcohol is octoxynol-40.
23. 20. The topical ophthalmic formulation of any one of claims 16 to 19, wherein the polyalkoxylated alcohol is about 0.05% by weight of the formulation.
24. 20. The topical ophthalmic formulation of any one of claims 16 to 19, having a pH of about 6.6 to about 7.
25. 20. The topical ophthalmic formulation of any one of claims 16 to 19, wherein in said formulation cyclosporine is present in one or more mixed nanomicelles.
26. 26. The topical ophthalmic formulation of claim 25, wherein the mixed nanomicelles have a particle size of about 5 to about 50 nm.
27. 26. The topical ophthalmic formulation of claim 25, wherein the mixed nanomicelles have a particle size of about 10 to about 40 nm.
28. 26. The topical ophthalmic formulation of claim 25, wherein the mixed nanomicelles have a particle size of about 15 nm.
